Nisa Investment Advisors LLC Raises Stake in Hologic, Inc. (NASDAQ:HOLX)

Nisa Investment Advisors LLC increased its stake in Hologic, Inc. (NASDAQ:HOLX) by 8.9% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 47,486 shares of the medical equipment provider’s stock after buying an additional 3,889 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Hologic were worth $3,393,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Macquarie Group Ltd. raised its stake in Hologic by 227.2% in the 2nd quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock valued at $435,485,000 after acquiring an additional 4,363,687 shares during the period. Norges Bank bought a new stake in Hologic in the 4th quarter valued at about $175,900,000. Arrowstreet Capital Limited Partnership raised its stake in Hologic by 110.6% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,896,174 shares of the medical equipment provider’s stock valued at $145,664,000 after acquiring an additional 995,854 shares during the period. Qube Research & Technologies Ltd raised its stake in Hologic by 117.2% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,378,258 shares of the medical equipment provider’s stock valued at $95,651,000 after acquiring an additional 743,557 shares during the period. Finally, Prudential Financial Inc. raised its stake in Hologic by 246.0% in the 1st quarter. Prudential Financial Inc. now owns 920,718 shares of the medical equipment provider’s stock valued at $70,730,000 after acquiring an additional 654,628 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on HOLX. Needham & Company LLC restated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Wednesday. UBS Group increased their price target on shares of Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a report on Friday, February 2nd. Raymond James increased their price target on shares of Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and increased their price target for the stock from $80.00 to $95.00 in a report on Wednesday, April 3rd. Finally, William Blair reissued an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Six research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $87.00.

Insider Buying and Selling at Hologic

In other news, CFO Karleen Marie Oberton sold 14,940 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the transaction, the chief financial officer now owns 103,916 shares in the company, valued at $7,793,700. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Karleen Marie Oberton sold 14,940 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the transaction, the chief financial officer now owns 103,916 shares in the company, valued at $7,793,700. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the transaction, the director now owns 1,572 shares in the company, valued at approximately $119,802.12. The disclosure for this sale can be found here. Insiders have sold 32,846 shares of company stock worth $2,473,443 over the last ninety days. Insiders own 1.75% of the company’s stock.

Hologic Stock Down 0.6 %

Shares of NASDAQ HOLX opened at $77.33 on Friday. Hologic, Inc. has a one year low of $64.02 and a one year high of $87.88. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. The firm’s 50 day simple moving average is $75.53 and its two-hundred day simple moving average is $72.33. The stock has a market capitalization of $18.15 billion, a P/E ratio of 36.65, a PEG ratio of 2.63 and a beta of 1.00.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $989.32 million. During the same period last year, the business earned $1.07 earnings per share. The business’s quarterly revenue was down 5.7% on a year-over-year basis. As a group, analysts expect that Hologic, Inc. will post 4.02 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.